Logo image of UBX

UNITY BIOTECHNOLOGY INC (UBX) Stock Fundamental Analysis

NASDAQ:UBX - Nasdaq - US91381U2006 - Common Stock - Currency: USD

2.23  +0.06 (+2.76%)

After market: 2.23 0 (0%)

Fundamental Rating

2

Taking everything into account, UBX scores 2 out of 10 in our fundamental rating. UBX was compared to 572 industry peers in the Biotechnology industry. UBX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. UBX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year UBX has reported negative net income.
In the past year UBX has reported a negative cash flow from operations.
In the past 5 years UBX always reported negative net income.
In the past 5 years UBX always reported negative operating cash flow.
UBX Yearly Net Income VS EBIT VS OCF VS FCFUBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of UBX (-52.05%) is comparable to the rest of the industry.
UBX has a Return On Equity of -141.02%. This is in the lower half of the industry: UBX underperforms 63.36% of its industry peers.
Industry RankSector Rank
ROA -52.05%
ROE -141.02%
ROIC N/A
ROA(3y)-52.52%
ROA(5y)-54.39%
ROE(3y)-110.66%
ROE(5y)-102.65%
ROIC(3y)N/A
ROIC(5y)N/A
UBX Yearly ROA, ROE, ROICUBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100

1.3 Margins

UBX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UBX Yearly Profit, Operating, Gross MarginsUBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K -20K

More info and screens

6

2. Health

2.1 Basic Checks

UBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
UBX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for UBX has been increased compared to 5 years ago.
There is no outstanding debt for UBX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
UBX Yearly Shares OutstandingUBX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
UBX Yearly Total Debt VS Total AssetsUBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -13.62, we must say that UBX is in the distress zone and has some risk of bankruptcy.
UBX has a Altman-Z score of -13.62. This is amonst the worse of the industry: UBX underperforms 80.89% of its industry peers.
UBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.62
ROIC/WACCN/A
WACC11.59%
UBX Yearly LT Debt VS Equity VS FCFUBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

UBX has a Current Ratio of 4.07. This indicates that UBX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.07, UBX perfoms like the industry average, outperforming 46.55% of the companies in the same industry.
UBX has a Quick Ratio of 4.07. This indicates that UBX is financially healthy and has no problem in meeting its short term obligations.
UBX's Quick ratio of 4.07 is in line compared to the rest of the industry. UBX outperforms 48.32% of its industry peers.
Industry RankSector Rank
Current Ratio 4.07
Quick Ratio 4.07
UBX Yearly Current Assets VS Current LiabilitesUBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 59.94% over the past year.
Looking at the last year, UBX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)59.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.42%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

UBX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.50% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.25%
EPS Next 2Y20.46%
EPS Next 3Y18.96%
EPS Next 5Y15.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
UBX Yearly Revenue VS EstimatesUBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
UBX Yearly EPS VS EstimatesUBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for UBX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for UBX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UBX Price Earnings VS Forward Price EarningsUBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UBX Per share dataUBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

UBX's earnings are expected to grow with 18.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.46%
EPS Next 3Y18.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for UBX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNITY BIOTECHNOLOGY INC

NASDAQ:UBX (2/4/2025, 8:13:03 PM)

After market: 2.23 0 (0%)

2.23

+0.06 (+2.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)N/A N/A
Inst Owners20.53%
Inst Owner Change-1.65%
Ins Owners0.87%
Ins Owner Change-0.04%
Market Cap37.58M
Analysts82.86
Price Target6.63 (197.31%)
Short Float %1.34%
Short Ratio0.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.52%
Min EPS beat(2)29.48%
Max EPS beat(2)33.56%
EPS beat(4)4
Avg EPS beat(4)39.16%
Min EPS beat(4)29.48%
Max EPS beat(4)61.55%
EPS beat(8)8
Avg EPS beat(8)26.59%
EPS beat(12)11
Avg EPS beat(12)25.95%
EPS beat(16)13
Avg EPS beat(16)21.88%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.5%
PT rev (3m)-2.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)1.62%
EPS NY rev (3m)3.28%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-33.33%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.9
P/tB 1.9
EV/EBITDA N/A
EPS(TTM)-1.31
EYN/A
EPS(NY)-1.4
Fwd EYN/A
FCF(TTM)-1.45
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS0
BVpS1.17
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.05%
ROE -141.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.52%
ROA(5y)-54.39%
ROE(3y)-110.66%
ROE(5y)-102.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.07
Quick Ratio 4.07
Altman-Z -13.62
F-Score5
WACC11.59%
ROIC/WACCN/A
Cap/Depr(3y)4.15%
Cap/Depr(5y)18.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.42%
EPS Next Y42.25%
EPS Next 2Y20.46%
EPS Next 3Y18.96%
EPS Next 5Y15.5%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y37.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.24%
EBIT Next 3Y5.38%
EBIT Next 5YN/A
FCF growth 1Y47.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.28%
OCF growth 3YN/A
OCF growth 5YN/A